



The ADDF/Belfer ApoE Therapeutics Innovation Program

Request for Proposals (RFP)

SUMMARY: The Alzheimer's Drug Discovery Foundation (ADDF) and the Robert A. and Renée E. Belfer Family Foundation established *The ADDF/Belfer ApoE Therapeutics Innovation Program* to accelerate the development of novel therapeutics specifically designed to target apoE pathological mechanisms. Although only ~20% of humans are *APOE* ϵ 4 carriers, these individuals account for up to 65% of all Alzheimer's disease cases. Therapies that target apoE are critically needed now. Recent scientific advances have made this a possibility.

This program will allow the ADDF to substantially build on its strategic investment in apoE drug discovery and development and will support both preclinical and clinical stage programs.

MECHANISM(S) OF SUPPORT: Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Please note that funding to biotechnology companies is typically made as a program related investment. The ADDF will provide 1 or 2 years funding for up to \$300,000 per application for pre-clinical programs, and up to \$1,000,000 per application for clinical trials of novel agents such as phase 1b or 2a studies employing biomarkers as outcome measures.

REVIEW PROCESS: The 2011 deadline date for applications is **October 5th**. Submission of a Letter of Intent (LOI) is required before **September 21st**. Applications will be confidentially reviewed by the ADDF and an external Scientific Review Committee. Applications from biotechnology companies will also be reviewed by the ADDF's external Business Advisory Board.

APPLICATION PROCEDURE:

All applications must be submitted electronically at www.alzdiscovery.org.

For program-related inquiries, please contact:

Diana Shineman, PhD, *Assistant Director for Scientific Affairs*
Phone: 212-901-8007 | E-mail: dshineman@alzdiscovery.org

For application submission inquiries, please contact:

Adam Liebling, *Senior Grants Manager*
Phone: 212-901-8005 | E-mail: aliebling@alzdiscovery.org

A Note on Confidentiality: All scientific reviewers shall hold in confidence and not disclose proprietary information received in connection with the Award Program. All review committee members are bound by ADDF's Confidentiality Disclosure Agreement to protect the confidentiality of such proprietary information to the full extent permitted by law.